Drug research

VGX-3100

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)NCT03180684	Inovio Pharmaceuticals	Phase 2	Completed	2020-07-23Actual
REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)NCT03185013	Inovio Pharmaceuticals	Phase 3	Completed	2020-07-08Actual
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2NCT03499795	Inovio Pharmaceuticals	Phase 2	Completed	2020-06-16Actual
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)NCT03721978	Inovio Pharmaceuticals	Phase 3	Completed	2022-08-23Actual

Inovio PharmaceuticalsCompletedPrimary completion: 2020-07-23 · Actual

Trial details

Inovio PharmaceuticalsCompletedPrimary completion: 2020-07-08 · Actual

Trial details

Inovio PharmaceuticalsCompletedPrimary completion: 2020-06-16 · Actual

Trial details

Inovio PharmaceuticalsCompletedPrimary completion: 2022-08-23 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.